المؤلفون: Ielasi L., Sansone V., Forgione A., Granito A., Benevento F., Tovoli F.

المساهمون: Ielasi L., Sansone V., Forgione A., Granito A., Benevento F., Tovoli F.

مصطلحات موضوعية: Atezolizumab, Bevacizumab, Cancer immunotherapy, Hepatocellular carcinoma, Immune checkpoint inhibitor, Monoclonal antibodie, Programmed cell death 1 ligand 1 (PD-L1) inhibitor, Antibodies, Monoclonal, Humanized, Human, Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms

وصف الملف: ELETTRONICO

Relation: info:eu-repo/semantics/altIdentifier/pmid/34151903; volume:57; issue:6; firstpage:365; lastpage:375; numberofpages:11; journal:DRUGS OF TODAY; https://hdl.handle.net/11585/899402; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85108138505

الاتاحة: https://hdl.handle.net/11585/899402
https://doi.org/10.1358/dot.2021.57.6.3264116